6.93 USD
+0.07 (+1.02%)
6.93 USD
0 (0%)
MDXG gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 534 industry peers in the Biotechnology industry. MDXG has an excellent financial health rating, but there are some minor concerns on its profitability. A decent growth rate in combination with a cheap valuation! Better keep an eye on MDXG. With these ratings, MDXG could be worth investigating further for value investing!.
1. Profitability
1.1 Basic Checks
In the past year MDXG was profitable.
In the past year MDXG had a positive cash flow from operations.
In multiple years MDXG reported negative net income over the last 5 years.
In multiple years MDXG reported negative operating cash flow during the last 5 years.
1.2 Ratios
With an excellent Return On Assets value of 12.80%, MDXG belongs to the best of the industry, outperforming 94.57% of the companies in the same industry.
MDXG's Return On Equity of 17.09% is amongst the best of the industry. MDXG outperforms 95.13% of its industry peers.
MDXG has a better Return On Invested Capital (15.15%) than 95.69% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 12.8% | ||
| ROE | 17.09% | ||
| ROIC | 15.15% |
ROA(3y)4.7%
ROA(5y)-7.18%
ROE(3y)1.74%
ROE(5y)-20.73%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
MDXG has a better Profit Margin (10.38%) than 92.13% of its industry peers.
MDXG's Operating Margin of 13.73% is amongst the best of the industry. MDXG outperforms 93.07% of its industry peers.
In the last couple of years the Operating Margin of MDXG has remained more or less at the same level.
MDXG's Gross Margin of 81.99% is amongst the best of the industry. MDXG outperforms 85.39% of its industry peers.
In the last couple of years the Gross Margin of MDXG has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 13.73% | ||
| PM (TTM) | 10.38% | ||
| GM | 81.99% |
OM growth 3YN/A
OM growth 5Y-1.06%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.19%
GM growth 5Y-0.67%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so MDXG is still creating some value.
MDXG has more shares outstanding than it did 1 year ago.
The number of shares outstanding for MDXG has been increased compared to 5 years ago.
MDXG has a better debt/assets ratio than last year.
2.2 Solvency
MDXG has an Altman-Z score of 9.89. This indicates that MDXG is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 9.89, MDXG belongs to the top of the industry, outperforming 81.84% of the companies in the same industry.
The Debt to FCF ratio of MDXG is 0.27, which is an excellent value as it means it would take MDXG, only 0.27 years of fcf income to pay off all of its debts.
MDXG has a Debt to FCF ratio of 0.27. This is amongst the best in the industry. MDXG outperforms 95.13% of its industry peers.
MDXG has a Debt/Equity ratio of 0.07. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.07, MDXG is not doing good in the industry: 61.61% of the companies in the same industry are doing better.
Although MDXG does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.07 | ||
| Debt/FCF | 0.27 | ||
| Altman-Z | 9.89 |
ROIC/WACC1.75
WACC8.66%
2.3 Liquidity
A Current Ratio of 4.41 indicates that MDXG has no problem at all paying its short term obligations.
With a Current ratio value of 4.41, MDXG perfoms like the industry average, outperforming 50.75% of the companies in the same industry.
MDXG has a Quick Ratio of 3.95. This indicates that MDXG is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of MDXG (3.95) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.41 | ||
| Quick Ratio | 3.95 |
3. Growth
3.1 Past
MDXG shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -35.71%.
MDXG shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 14.77%.
The Revenue has been growing slightly by 3.11% on average over the past years.
EPS 1Y (TTM)-35.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%200%
Revenue 1Y (TTM)14.77%
Revenue growth 3Y10.5%
Revenue growth 5Y3.11%
Sales Q2Q%35.3%
3.2 Future
The Earnings Per Share is expected to grow by 17.40% on average over the next years. This is quite good.
MDXG is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 14.49% yearly.
EPS Next Y49.48%
EPS Next 2Y8.55%
EPS Next 3Y17.4%
EPS Next 5YN/A
Revenue Next Year17.88%
Revenue Next 2Y9.84%
Revenue Next 3Y10.43%
Revenue Next 5Y14.49%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 19.25, which indicates a rather expensive current valuation of MDXG.
Based on the Price/Earnings ratio, MDXG is valued cheaply inside the industry as 94.19% of the companies are valued more expensively.
MDXG's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 26.46.
MDXG is valuated rather expensively with a Price/Forward Earnings ratio of 20.28.
Based on the Price/Forward Earnings ratio, MDXG is valued cheaper than 94.19% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 36.10, MDXG is valued a bit cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 19.25 | ||
| Fwd PE | 20.28 |
4.2 Price Multiples
MDXG's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. MDXG is cheaper than 95.51% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of MDXG indicates a rather cheap valuation: MDXG is cheaper than 96.25% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 15.36 | ||
| EV/EBITDA | 12.99 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
MDXG has a very decent profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as MDXG's earnings are expected to grow with 17.40% in the coming years.
PEG (NY)0.39
PEG (5Y)N/A
EPS Next 2Y8.55%
EPS Next 3Y17.4%
5. Dividend
5.1 Amount
MDXG does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
6.93
+0.07 (+1.02%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners71.57%
Inst Owner Change-0.71%
Ins Owners1.83%
Ins Owner Change0.17%
Market Cap1.03B
Revenue(TTM)393.44M
Net Income(TTM)40.83M
Analysts81.82
Price Target12.44 (79.51%)
Short Float %3.22%
Short Ratio5.42
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)95.82%
Min EPS beat(2)81.55%
Max EPS beat(2)110.08%
EPS beat(4)3
Avg EPS beat(4)41.67%
Min EPS beat(4)-31.92%
Max EPS beat(4)110.08%
EPS beat(8)7
Avg EPS beat(8)78.91%
EPS beat(12)11
Avg EPS beat(12)70.05%
EPS beat(16)12
Avg EPS beat(16)53.63%
Revenue beat(2)2
Avg Revenue beat(2)12.56%
Min Revenue beat(2)6.68%
Max Revenue beat(2)18.43%
Revenue beat(4)4
Avg Revenue beat(4)6.82%
Min Revenue beat(4)0.32%
Max Revenue beat(4)18.43%
Revenue beat(8)6
Avg Revenue beat(8)3.48%
Revenue beat(12)9
Avg Revenue beat(12)3.71%
Revenue beat(16)12
Avg Revenue beat(16)3.45%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)21.15%
EPS NQ rev (3m)21.15%
EPS NY rev (1m)30.77%
EPS NY rev (3m)30.77%
Revenue NQ rev (1m)2.37%
Revenue NQ rev (3m)2.37%
Revenue NY rev (1m)5.61%
Revenue NY rev (3m)5.61%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 19.25 | ||
| Fwd PE | 20.28 | ||
| P/S | 2.61 | ||
| P/FCF | 15.36 | ||
| P/OCF | 15.13 | ||
| P/B | 4.3 | ||
| P/tB | 4.93 | ||
| EV/EBITDA | 12.99 |
EPS(TTM)0.36
EY5.19%
EPS(NY)0.34
Fwd EY4.93%
FCF(TTM)0.45
FCFY6.51%
OCF(TTM)0.46
OCFY6.61%
SpS2.66
BVpS1.61
TBVpS1.41
PEG (NY)0.39
PEG (5Y)N/A
Graham Number3.62
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 12.8% | ||
| ROE | 17.09% | ||
| ROCE | 20.67% | ||
| ROIC | 15.15% | ||
| ROICexc | 33.2% | ||
| ROICexgc | 44.66% | ||
| OM | 13.73% | ||
| PM (TTM) | 10.38% | ||
| GM | 81.99% | ||
| FCFM | 16.98% |
ROA(3y)4.7%
ROA(5y)-7.18%
ROE(3y)1.74%
ROE(5y)-20.73%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5Y-47.46%
ROICexc growth 3YN/A
ROICexc growth 5Y-21.46%
OM growth 3YN/A
OM growth 5Y-1.06%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.19%
GM growth 5Y-0.67%
F-Score6
Asset Turnover1.23
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.07 | ||
| Debt/FCF | 0.27 | ||
| Debt/EBITDA | 0.25 | ||
| Cap/Depr | 6.96% | ||
| Cap/Sales | 0.26% | ||
| Interest Coverage | 36.69 | ||
| Cash Conversion | 98.8% | ||
| Profit Quality | 163.64% | ||
| Current Ratio | 4.41 | ||
| Quick Ratio | 3.95 | ||
| Altman-Z | 9.89 |
F-Score6
WACC8.66%
ROIC/WACC1.75
Cap/Depr(3y)52.31%
Cap/Depr(5y)58.09%
Cap/Sales(3y)0.72%
Cap/Sales(5y)1.07%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-35.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%200%
EPS Next Y49.48%
EPS Next 2Y8.55%
EPS Next 3Y17.4%
EPS Next 5YN/A
Revenue 1Y (TTM)14.77%
Revenue growth 3Y10.5%
Revenue growth 5Y3.11%
Sales Q2Q%35.3%
Revenue Next Year17.88%
Revenue Next 2Y9.84%
Revenue Next 3Y10.43%
Revenue Next 5Y14.49%
EBIT growth 1Y-14.78%
EBIT growth 3YN/A
EBIT growth 5Y2.02%
EBIT Next Year35.54%
EBIT Next 3Y15.54%
EBIT Next 5Y22.59%
FCF growth 1Y787.24%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y522.28%
OCF growth 3YN/A
OCF growth 5YN/A
MIMEDX GROUP INC / MDXG FAQ
Can you provide the ChartMill fundamental rating for MIMEDX GROUP INC?
ChartMill assigns a fundamental rating of 6 / 10 to MDXG.
What is the valuation status of MIMEDX GROUP INC (MDXG) stock?
ChartMill assigns a valuation rating of 7 / 10 to MIMEDX GROUP INC (MDXG). This can be considered as Undervalued.
What is the profitability of MDXG stock?
MIMEDX GROUP INC (MDXG) has a profitability rating of 6 / 10.
What is the valuation of MIMEDX GROUP INC based on its PE and PB ratios?
The Price/Earnings (PE) ratio for MIMEDX GROUP INC (MDXG) is 19.25 and the Price/Book (PB) ratio is 4.3.
What is the financial health of MIMEDX GROUP INC (MDXG) stock?
The financial health rating of MIMEDX GROUP INC (MDXG) is 7 / 10.